ERBB2 and breast carcinoma: Nowadays, HER2 has turned out to be somewhat of a good prognostic biomarker because of Herceptin treatment recommended by National Comprehensive Cancer Network (NCCN) breast cancer guideline (Gradishar et al., 2021).